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Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2) infection. The infection started as an outbreak
of pneumonia-like symptoms in Wuhan, China. Within a few weeks, it spread
across the entire globe resulting in millions of cases and thousands of deaths.
While respiratory symptoms and complications are well-defined and can be
severe, non-respiratory symptoms of COVID-19 are increasingly being recognized.
Gastrointestinal manifestations such as nausea, vomiting, diarrhea, and abdominal pain
have been added to the list of common COVID-19 symptoms. Their prevalence has been
increasing, probably due to increased recognition and experience with the pandemic.
Furthermore, diarrhea and stool testing may change prevalence and transmission rates
due to suspicion for fecal-oral transmission of the COVID-19. Due to this risk, various
countries have started testing wastewater and sewage systems to examine its role
in the spread of SARS-CoV-2 among communities. In this review article, we describe
the common gastrointestinal manifestations in COVID-19, their prevalence based upon
the current literature, and highlight the importance of early recognition and prompt
attention. We also note the role of fecal-oral transmission. Furthermore, the mechanisms
of these symptoms, the role of medications, and potential contributing factors are
also elaborated.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) manifesting mainly as pneumonia, acute respiratory distress syndrome, and
multiorgan failure (1). Though originated in Wuhan, China, as a cluster of pneumonia-like
presentation, soon it spread across the globe. As of July 28th, 2020, SARS-CoV-2 has affected
all countries and territories in the World, with more than 17 million cases and 660,000 deaths
(2). Non-respiratory manifestations are increasingly being recognized in COVID-19 (3, 4).
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GI symptoms though less common compared to respiratory
symptoms have gained increased significance lately (5). The
Center for Disease Control (CDC) added multiple GI symptoms
of COVID-19, which can coexist with respiratory symptoms, or
they can be the only presentation of the disease (3). Anorexia,
nausea, vomiting, diarrhea, and abdominal pain are some of the
frequently observed gastrointestinal (GI) symptoms in COVID-
19 patients (6). Additionally, GI bleeding, acute pancreatitis, and
colitis have also been reported.
There is a potential of fecal-oral transmission due to the
presence of the viral RNA in stools, especially in asymptomatic
individuals. Due to this concern, sewage and the wastewater
is being analyzed to detect the SARS-CoV-2 virus, examine
the role of feco-oral transmission in the community, and
identify mitigation strategies (7). Early identification and prompt
attention to GI symptoms are critical because hospitalized
COVID-19 patients with concomitant GI symptoms have been
found to develop severe disease. Also, understanding the
prevalence and mechanisms of GI manifestations can help to
better characterization of these symptoms. In addition, educating
patients about these symptoms can not only identify COVID-19
cases at an early stage but also can prevent potential spread to
uninfected individuals.
ANOREXIA
Loss of appetite (anorexia) is one of the most common GI
symptoms in COVID-19 patients (Table 1). The presence of
anorexia in COVID19 is mostly underestimated and under-
reported because of its non-specific nature. Prevalence among
different studies ranged from 12.2 to 50.2% (8–10). A pooled
analysis of multiple studies showed an overall prevalence of
26.8% (11). Anorexia is also frequently associated with other
GI symptoms of vomiting, abdominal pain, and diarrhea.
Pathophysiology of anorexia could be related to acute viral
prodrome associated with COVID-19. Acute inflammation can
increase the cytokine load such interleukins (IL-2, IL-7), tumor
necrosis factors (TNF) which contribute to cytokine storm seen
in COVID-19 (Table 2). In addition, altered or change in taste
(dysgeusia) noted in these patients can further exacerbate loss of
appetite (26).
NAUSEA AND VOMITING
COVID-19 patients can have nausea and vomiting as their only
symptoms at presentation or as a combination with other GI
symptoms, including anorexia, diarrhea, and rarely abdominal
pain. A pooled prevalence of 7.8% (95% CI, 7.1–8.5%) was noted
for nausea or vomiting from 26 studies spanning among different
nations. Similar to other GI symptoms, the prevalence of nausea
and vomiting among Chinese studies was lower (5.2%) compared
to studies from other countries (14.9%). In one study’ s Nobel
et al. (27) noted that the presence of nausea or vomiting in as
high as 22.7% patients (63 patients developed nausea among 278
patients, 95%CI, 17.9–28%). Similarly, Cholankeril et al. (28) and
Hajifathalian et al. (29) reported the prevalence of symptoms of
nausea and vomiting as 10.3 and 15.9%, respectively. While the
precise reasons remain unclear, nausea, and vomiting could be
related to a combination of effects on the gut and central nervous
system (CNS) (13). After entry of SARS-CoV-2 into the GI tract,
it can gain access to portal circulation and can affect the vagus
nerve either through vascular or lymphatic routes. In addition,
the cytopathic effect caused by SARS-CoV-2 combined with
cytokine storm can stimulate central and peripheral (autonomic
nervous) pathways, culminates into a sensation of nausea (with
or without vomiting). Once neural pathways are stimulated,
gastric dysrhythmia can occur, resulting in vomiting (30).
Furthermore, antibiotics and antiviral agents are frequently
used in COVID-19 patients, which further exacerbates their
symptoms (31). If these factors contribute in an isolated fashion
or combination is unknown.
DIARRHEA
Diarrhea is a commonly noted GI symptom in COVID-19
patients. It has significant public health importance given
its potential for feco-oral transmission of disease. A pooled
prevalence of multiple studies showed an overall prevalence of
diarrhea of 5–10% (11, 32). There is a wide range of prevalence
noted in multiple studies ranging from 2 to 50% (33). In a
large cohort of 1,059 patients, 234 cases of diarrhea were noted
with a prevalence of 22.1% (95% CI, 19.6–24.7%) (29). Similarly,
among 355 cases in the Hubei province of China, 130 patients
developed diarrhea with a prevalence of 36.6% (95% CI, 31.6–
41.9%) (34). Several factors could be responsible for variation in
the prevalence of diarrhea in these studies. Documentation of GI
symptoms at the time of hospitalization, high suspicion, and early
recognition, and if patients are treated either in an outpatient or
inpatient basis, could be responsible for this variation.
Despite the high frequency of diarrhea, standardized criteria
for diagnosis, and grading the severity of diarrhea are missing
in most studies. Patients with a viral illness can present with
a transient episode of loose stools with or without other GI
symptoms. While persistent diarrhea (3 or more loose stools
for more than 48 h) is significant, this definition is rarely used
in the studies. Moreover, if diarrhea is not present at the
admission, it becomes challenging to ascertain the cause of
diarrhea. Several confounding variables, such as the use of enteral
feeding (tube feeds), antiviral and antibiotics, altered gut flora,
hyperinflammatory response, secondary bacterial infections, use
of proton pump inhibitors (PPI) can potentially cause diarrhea
in hospitalized COVID-19 patients (35). In order to determine if
the persistent diarrhea is from SARS-CoV-2, evidence of direct
viral-induced cytopathy (through histology or stool viral RNA
positivity) should be documented.
ABDOMINAL PAIN
Patients with COVID-19 can present with abdominal pain, which
is less frequent as compared to anorexia, nausea/vomiting, or
diarrhea. The prevalence of abdominal pain ranges from 3.9 to
6.8% (10, 11, 28, 29, 36). There is no consensus regarding the
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TABLE 1 | Typical and atypical GI symptoms in COVID-19.
Typical Atypical
Loss of appetite (anorexia) Altered taste (dysgeusia)
Nausea and vomiting Gastrointestinal bleeding
Diarrhea Secondary bacterial infection (Clostridium difficile)
Abdominal pain
TABLE 2 | Mechanisms of GI symptoms.
Effect Contributing factors
Viral cytopathic effect • The entry of SARS-CoV-2 via ACE-2 receptors in
GI glandular epithelium (12)
• Isolated of viral RNA particles in stools of
COVID-19 patients (13)
Altered gut microbiota • Use of multiple antimicrobial agents
• Change in gut microbial composition from viral
proinflammatory mediators (14)
• Abnormal mTOR activity and decreased
antimicrobial activity (15)
• Increased susceptibility for infections (Clostridium
difficile) (16)
• Hypochlorhydria induced by antisecretory agents
(such as the use of proton pump inhibitors) (17)
• Altered gut-lung axis (18)
Inflammation • Increased cytokine release such as interleukins (IL-
2, 7), tumor necrosis factor, granulocyte monocyte
colony-stimulating factors (cytokine storm) (19)
• The altered gut-brain axis (20)
• Increased fecal calprotectin (21)
Worsening of prior GI
conditions
• Overexpression of ACE-2 in the inflamed gut in
inflammatory bowel disease (21)
• Worsening of prior irritable bowel syndrome
Secondary infections • Increased risk of clostridium difficile (16)
Others • Intestinal ischemia (22, 23)
• Viral colitis (24)
• Altered GI epithelial integrity (25)
• Altered enteric nervous system output (20)
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; ACE-2, angiotensin-
converting enzyme-2.
severity and duration of abdominal pain in COVID-19 patients.
The location of the pain could be the right upper quadrant or
epigastric or generalized. Few cases of COVID-19 presenting as
acute abdomen has been reported (37). The precise mechanism
for abdominal pain is unclear. Furthermore, any viral illness as
a part of the prodrome can cause transient abdominal cramping
and discomfort. Furthermore, abdominal pain can be combined
with other GI symptoms of anorexia, nausea with or without
vomiting. After the entry into GI tract, SARS-CoV-2 can exert
its cytopathic/inflammatory changes, which can potentially lead
to visceral pain. If this is a somatic due to the involvement of
the peritoneum or a referred pain is unknown. Sporadic reports
of pancreatitis have also been reported in COVID-19 patients
(38). Additionally, high expression of ACE-2 receptors is noted in
the pancreatic tissue, which makes it susceptible to its cytopathic
effects. It can lead to leakage of pancreatic lipase and fatty acid
oxidation. Few autopsy reports have shown ongoing pancreatic
injury in COVID-19 patients without clinically evident acute
pancreatitis (18). Hyperlipasemia has been identified in these
patients in multiple studies (39, 40). It is unclear if a low level
of elevated lipase is from viral pancreatic inflammation or as a
part of viral gastroenteritis (38, 39).
ADDITIONAL DIGESTIVE SYMPTOMS
In addition to the above GI symptoms, other atypical
manifestations such as changes or loss of smell and taste and
GI bleeding have been documented in COVID-19 patients (17,
41). Aziz et al. noted that taste changes (ageusia/dysgeusia) are
prevalent in up to 49.8% (95% CI: 8.2–91.5%, I2 = 99.6%)
patients, although this meta-analysis had limited number of
studies (26). Lin et al. reported a few cases of GI bleeding with
viral RNA isolation from esophageal samples (12). Furthermore,
endoscopically herpetic erosion was noted in these patients.
If SARS-CoV-2 cytopathic effects lead to these erosions or if
the virus is a bystander remains unclear. Secondary bacterial
infections such as Clostridium difficile infections were noted
in COVID-19 patients, probably due to the widespread use of
antibiotics in these patients. Additionally, altered gut flora is




SARS-CoV-2 enters the mucous membranes (nose, oral cavity)
through its well-documented functional receptor angiotensin-
converting enzyme-2 (ACE-2) (15, 26). While it can make its way
to the gastric lumen via salivary secretions, it is subjected to the
adverse effect of the acidic environment of the stomach. A pH
of <2 significantly affects the life of the virus (16, 19). Patients
with hypochlorhydria are susceptible to get a viral infection
because of a higher viral load entering the small intestine
(20). ACE-2 receptor concentrations differ among different GI
tissues, with high expression noted in ileal enterocytes (21). Once
SARS-CoV-2 enters the enterocytes, viral synthesis, replication
can continue, and a cytopathic effect is noted (evidenced by
intracellular staining of viral nucleocapsid) (22). The virus can
continue its journey from here to other organs via the portal
circulation. These changes can potentially lead to stool viral
RNA positivity. If the presence of viral RNA in the stool is
indicative of cytopathic changes or just a bystander needs further
validation (Table 2).
Gut flora plays a significant role in maintaining GI
homeostasis, and any perturbations can lead to diarrhea and
various GI symptoms such as nausea and vomiting. COVID-
19 patients are at high risk of microbiome alterations. We
highlight 6 of the key factors for gut flora alteration in
COVID patients. First, viral infections can increase the release
of proinflammatory cytokines, which can alter gut flora (23).
It is well-recognized that SARS-CoV-2 patients have elevated
cytokines and markers of inflammation (24). Additionally, the
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FIGURE 1 | Schematic representation of various gastrointestinal (GI) manifestations with their mechanisms. SARS-CoV-2 gains entry via mucous membranes of the
oral cavity enters the stomach and small intestine to exert its cytopathic effect. Additionally, gut inflammation, altered gut flora, drug-induced changes, worsening of
pre-existing GI condition, and secondary infections could contribute to these symptoms.
use of various antimicrobial medications (antibiotics, antivirals)
can change the composition of flora, which can predispose
individuals to GI adverse effects (31). A third factor, as respiratory
symptoms are exceedingly common in COVID-19 patients,
change in lung flora can contribute to the potential change
in gut flora (14). This “gut-lung” axis is increasingly being
recognized as a potential cause of GI symptoms in individuals
with respiratory manifestations (14). A fourth factor is that
altered flora can lead to a change in the ratio of pathogenic
organisms, potentially leading to infections such as clostridium
difficile. Recent reports of such infections were noted in COVID-
19 patients (25). Fifth, the use of enteral nutrition, such as
tube feeds, can further alter the gut microbiome already affected
due to the aforementioned causes. Finally, ACE-2 receptor
binding has been shown to alter flora by its aberrant mTOR
activity (42).
All of the above mechanisms are only putative, as there
is no reliable evidence if these mechanisms play a role
independently or in combination in the development of GI
symptoms in COVID-19 patients. Patients with pre-existing
GI conditions such as inflammatory bowel disease (IBD) and
malabsorption syndromes etc. are at risk of worsening GI
symptoms if infected with SARS-CoV-2 (43, 44). While changes
in the gut flora are universal in these populations, ACE-2
expression is elevated in IBD and inflammatory states (44).
Fecal calprotectin, which is a marker for bowel inflammation,
has been noted to be elevated in COVID-19 individuals
with persistent diarrhea (45). If such increased expression
predisposes these individuals to worsening symptoms needs
to be studied. Furthermore, the enteric nervous system is
integrally associated with GI motility, and any perturbation in
these pathways can lead to worsening of GI symptoms (46)
(Figure 1).
GI MANIFESTATIONS AND COVID-19
SEVERITY
As noted above, patients with COVID-19 frequently present
with GI manifestations. However, data on the correlation
between GI manifestations and severity of COVID-19 has
been variable (6, 47–50). Ramachandran et al. studied 150
hospitalized patients with COVID-19 with and without GI
symptoms and reported no difference in length of stay or need
for mechanical ventilation or mortality (6). Pan et al. reported
that as the severity of COVID-19 increased, GI symptoms
were more pronounced (47). A pooled analysis of multiple
studies evaluated the correlation between GI symptoms and
COVID-19 severity. Abdominal pain was associated with 4
fold increased odds of severe disease, marginally increased
odds with nausea/vomiting, and no correction with diarrhea
(48). Further dedicated studies are needed to evaluate these
correlations of GI symptoms and COVID-19 severity without
potential confounders.
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FECAL-ORAL SPREAD
Diarrhea can predispose the community to the fecal-oral spread
of the disease. Previous outbreaks from other coronaviruses
(SARS outbreak in 2003) showed that sewage could be a source of
infection (51). Randazzo et al. noted that evaluating waste-water
plant systems early in the outbreak can help in identifying the
spread of infection even before patients exhibit clinical symptoms
(7). These methods can potentially help in developing public
health strategies and policies to interfere with the spread of
the disease.
In patients with diarrhea, stool positivity is noted in almost
half of the cases. A systematic review of multiple studies showed
a pooled prevalence of 48.1% (95% CI, 38.3–57.9%) for stool
positivity (11). It is debatable if this stool positivity can lead
to infectivity and spread of disease to uninfected individuals.
COVID-19 Patients can have viral RNA stools positivity for an
extended period (up to 14 days) even after the resolution of
respiratory symptoms (52, 53). Studies have shown a prevalence
of 30 to 82% of stool positivity after viral respiratory clearance
(22, 54, 55). Cheung et al. noted a highermedian fecal viral load in
patients with positive stool viral RNA as compared to individuals
without diarrhea (5.1 log10 copies/ml vs. 3.9 log10 copies/ml; p=
0.06) (32). These factors play a significant role in the development
of mitigation strategies and standard protocol before a patient
could be deemed non-infective after discharge from the hospital.
COVID-19 AND GASTROINTESTINAL
ENDOSCOPIES
Endoscopic procedures can increase the exposure of the
endoscopy staff with spillage of GI secretions, especially with
the use of multiple devices (56, 57). Due to the inherent
nature of the procedures with proximity to oral-pharyngeal
secretions, endoscopy staff can get exposed to increasing the
risk of transmission (56). Furthermore, endoscopes such as
duodenoscopes are at risk of microbial contamination due to
their inherent design (elevator) (58). As endoscopy centers
resume their workflow, significant changes in triaging have been
implemented with pre-procedural testing and active screening
for COVID-19 symptoms. In addition to classical symptoms of
fever, cough, shortness of breath, altered taste, additional GI
symptoms of nausea, vomiting, diarrhea, and abdominal pain
should be a part of a pre-operative questionnaire for elective
procedures for those centers in high prevalence areas (59).
Multiple GI societies have recommended guidelines for the use
of negative pressure rooms, especially for patients infected with
SARS-CoV-2 (60, 61). During the procedure, endoscopists, and
staff should take adequate precautions such as the use of personal
protective equipment (PPE) to prevent transmission of infection.
Additionally, if the disinfection of endoscopic equipment is
inadequate, it can theoretically lead to contamination and spread
(58, 62). Repici et al. reported data to assess the risk of COVID-
19 transmission in GI endoscopy (63). A study composed of
851 patients from Northern Italy showed eight patients had
symptoms of fever, cough of which only one patient turned
COVID-19 positive. None of the patient required hospitalization,
suggests a very low risk of endoscopic transmission SARS-CoV-2
for patients. Furthermore, Repici et al. assessed 968 health care
workers (HCW) from 41 hospitals, 42 (4.3%) tested positive, and
six (0.6%) were hospitalized (63). Of the 42 HCWs who tested
positive, 85.7% occurred prior to the introduction of PPE or
reduction of endoscopy volume. All of these point toward the
low risk of transmission of SARS-CoV-2 during endoscopy (63).
Nevertheless, endoscopy staff should adhere to strict protective
measures to avoid any amount of transmission.
Multiple national and international societies recommended
deferral of non-urgent and elective procedures during the
“phase 1” of the pandemic. This led to significant changes in
the functioning of endoscopy units. In countries like Brazil,
endoscopy staff has been divided into COVID and non-COVID
teams to facilitate the flow in the unit (64). Mask mandates have
been issued for all the endoscopy staff (56, 57, 61). Layouts of
endoscopy units were changed based on risk-based color-coding
of the suite, waiting, and recovery rooms (65) Pre-procedure
testing has been implemented across multiple endoscopy units
(66). Studies showed a reduction of procedure volume up
to 99% (67). Studies showed that these changes have led to
a decrease in colon cancer screenings by almost 85% (68).
Deferral of these procedures was predominately elective (such as
screening, surveillance), resulting in potentially increased load
during recovery or “phase 2.” Although this is dependent on
the rate of infectivity in the community and indication, it is
likely expected that increased case volumes and backlogs will
occur post-pandemic.
MEDICATIONS AND GI SYMPTOMS
Patients with COVID-19 are subjected to increased
pharmacological interventions. Due to suspicion for secondary
bacterial infections, they are empirically treated with antibiotics
such as fluoroquinolones and cephalosporins. Antiviral agents
such as ritonavir-lopinavir, hydroxychloroquine, remdesivir,
and tocilizumab can potentially cause nausea, vomiting, and
diarrhea (69–72). Other agents such as azithromycin, oseltamivir,
favipiravir may be used in COVID-19 patients at different stages
of the disease, which can all contribute to the GI symptoms. If
these agents directly cause the GI symptoms or contribute to
the cytopathic effects of the SARS-CoV-2 is unclear. Recently,
the use of PPI and resulting hypochlorhydria being recognized
as a potential for increased positivity of COVID-19. A recent
retrospective study showed that pre-hospitalization PPI exposure
in hospitalized COVID-19 patients associated with a higher risk
of the need for mechanical ventilation and higher mortality
(19, 20, 73, 74). Gastric acid has shown to have neutralizing
effects on many bacteria and viruses. The similar effect of gastric
acid is also proposed on its neutralizing effect on SAR-CoV-2 PPI
ca cause profound hypochlorhydria, which could be the reason
for the higher risk of COVID-19 in these patients. However,
a similar effect was not observed for the H2blockers, which
are weak acid-suppressing medications. Further studies are
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required to discern if PPI use increases the viral stools shedding
in COVID-19.
CONCLUSION
GI manifestations are increasingly being recognized in COVID-
19 patients. Some studies have shown severe disease in these
patients, which could be due to increased viral load and
involvement of multiple organ systems. It is important to
recognize that some patients with COVI-19 may have only
GI symptoms either prior to or in the absence of subsequent
respiratory symptoms. These symptoms can be varied in
presentation–from loss of sense of taste and smell to severe
GI upset with diarrhea and abdominal pain. Individuals with
these symptoms working in healthcare or other higher-risk
environments should be checked for Covi-19 and potentially
isolates. A strict medical definition of diarrhea should be
observed in these patients to differentiate if the virus itself
directly causing diarrhea or it is due to the patients’ overall
sickness. Other potential causes of diarrhea, such as clostridium
difficile and antibiotics-associated diarrhea, need to be ruled
out in these patients. The role of viral stool positivity in
the transmission of the COVID-19 needs to be further
studied. Multiple studies have shown that endoscopy staff is
at higher risk of acquiring SARS-CoV-2 infection, possibly
because of aerosolization of the secretions during suctioning. As
endoscopies procedures are being resumed, strict adherence to
universal precautions and use of personal protective equipment
is needed. The patient viral transmission during the endoscopic
procedures has not been reported but is theoretically possible
as there are reports viral transmission with other kinds
of viruses.
There is an urgent need for the standardization
of stool testing, disease severity, a strict definition
of GI symptoms, and evaluation of potential
confounders. Nevertheless, advances made so far have
increased our understanding of the GI symptoms,
and they will likely continue to evolve as this
pandemic unfolds.
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